Shengnan Li

863 citations
30 papers · 549 indexed · h-index 13
Topics
Pancreatic and Hepatic Oncology Research (7 papers)Cancer Immunotherapy and Biomarkers (5 papers)Cancer Cells and Metastasis (3 papers)
Journals
SHILAP Revista de lepidopterologíaEnvironmental Science & TechnologyHepatology
Partner nations
ChinaAustraliaHong Kong

In The Last Decade

Shengnan Li

30 papers receiving 541 citations

Peers

Shengnan Li
Comparison fields: 5 of 99
  • Molecular Biology 165
  • Oncology 149
  • Surgery 86
  • Immunology 68
  • Pulmonary and Respiratory Medicine 65
Replace K. Noda with:
K. Noda Japan
Qian Liang China
Hideaki Nakashima Japan
D. Wilkinson United Kingdom
Takeshi Saito Japan
Jae‐Hwan Jeong South Korea
Xin Tian China
Michael T. Meister Germany
Yanan Xing China
Shengnan Li relative to K. Noda Japan K. Noda's profile →
Citations per field
00.5×20×40×51.5×
K. Noda · 1×
Citations per year

Countries citing papers authored by Shengnan Li

Since Specialization
Citations

This map shows the geographic impact of Shengnan Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengnan Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengnan Li more than expected).

Fields of papers citing papers by Shengnan Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shengnan Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengnan Li. The network helps show where Shengnan Li may publish in the future.

Co-authorship network of co-authors of Shengnan Li

This figure shows the co-authorship network connecting the top 25 collaborators of Shengnan Li. A scholar is included among the top collaborators of Shengnan Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shengnan Li. Shengnan Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 5
2 7
3 43
4 5
5 22
6 2
7 3
8 11
9 19
10 14
11 69
12 37
13 71
14 16
15 15
16 6
17 30
18 8
19 9
20 2

About Shengnan Li

Shengnan Li is a scholar working on Anatomy, Oncology and Transplantation, having authored 30 papers that have together received 549 indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cancer Cells and Metastasis (3 papers). The work is most often cited by research in Oncology (149 citations), Renewable Energy, Sustainability and the Environment (58 citations) and Cancer Research (53 citations). Shengnan Li has collaborated with scholars based in China, Australia and Hong Kong. Frequent co-authors include Danyi Mao, Parikshit Asutosh Khadaroo, Zefeng Shen, Lihu Gu, Ping Chen, Bo Yang, Xiaoshun Zhang, Derry Minyao Ng, Haofei Li and Lin Jiang. Their work appears in journals such as SHILAP Revista de lepidopterología, Environmental Science & Technology and Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026